Sign In
Buy KVUE
$16.83
-0.490 (-2.83%)
At Close: Jun 03, 2026
Kenvue (KVUE) Q2 Earnings Top Estimates
08:55am, Thursday, 07'th Aug 2025
Kenvue (KVUE) came out with quarterly earnings of $0.29 per share, beating the Zacks Consensus Estimate of $0.28 per share. This compares to earnings of $0.32 per share a year ago.
Kenvue meets profit estimates amid strategic review
06:55am, Thursday, 07'th Aug 2025
Kenvue reported a second-quarter profit largely in line with Wall Street estimates on Thursday, amid a strategic review at the consumer health company.
Kenvue Reports Second Quarter 2025 Results
06:45am, Thursday, 07'th Aug 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the second quarter ended June 29, 2025. “Kenvue has a strong portfolio of world-class, category-defining
Should You Buy Kenvue Stock At $22?
10:50am, Tuesday, 05'th Aug 2025
Although there has been a recent increase of 21% that aligns with the broader market gains, Kenvue (NYSE: KVUE) offers limited investment appeal at its current valuations. Our thorough analysis encomp
Countdown to Kenvue (KVUE) Q2 Earnings: A Look at Estimates Beyond Revenue and EPS
10:16am, Monday, 04'th Aug 2025
Besides Wall Street's top-and-bottom-line estimates for Kenvue (KVUE), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quar
Analysts Estimate Kenvue (KVUE) to Report a Decline in Earnings: What to Look Out for
11:08am, Thursday, 31'st Jul 2025
Kenvue (KVUE) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
4 Safe High-Yielding Dividend Aristocrats Are Our Top Picks in a Dangerous Market
07:18am, Wednesday, 30'th Jul 2025
Investors seeking defensive companies that pay substantial dividends are drawn to the Dividend Aristocrats, and with good reason.
Kenvue Increases Quarterly Cash Dividend
06:45am, Wednesday, 30'th Jul 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced its Board of Directors declared a quarterly dividend of $0.2075 per share on its common stock, which represents a 1.2 percent in
20 Kiplinger July Dividend Favorites: No Cigars
11:45am, Sunday, 27'th Jul 2025
Dividend stocks are regaining appeal as interest rates fall, offering higher returns and lower risk compared to non-dividend payers over the long term. Top Kiplinger dividend 'dogs' are projected to d
Kenvue to Announce Second Quarter 2025 Results on August 7, 2025
06:45am, Friday, 25'th Jul 2025
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2025 financial results before the market opens on August 7, 2025. The company will host a conference call and w
Want to Generate at Least $1,000 in Passive Income Per Year? Invest $26,000 in This Dividend King Stock.
03:07am, Tuesday, 15'th Jul 2025
The stock market has historically been a highly effective tool for compounding wealth over time. Another way to use the stock market to achieve your financial goals is to generate income from dividend
Kenvue announces CEO transition and strategic review
11:07am, Monday, 14'th Jul 2025
Kenvue (NYSE:KVUE) has announced a CEO transition and the launch of a strategic review process aimed at enhancing shareholder value and improving the long-term performance of the consumer health comp
Call Traders Circle Tylenol Parent Amid C-Suite Swap
10:45am, Monday, 14'th Jul 2025
Tylenol parent Kenvue Inc (NASDAQ:KVUE) is up 1.4% to trade at $21.64, after the company fired its CEO Thibaut Mongon amid efforts to revamp performance.
Kenvue stock rises on CEO exit as company launches strategic review and warns of lower sales
09:37am, Monday, 14'th Jul 2025
Kenvue, the Johnson & Johnson spinoff that owns brands such as Tylenol and Benadryl, announced Monday that Chief Executive Officer Thibaut Mongon has stepped down. Kenvue shares were up by more than 6
Kenvue Seeks Its Own Band-Aid With CEO Departure and Strategic Review. The Stock Rises.
07:22am, Monday, 14'th Jul 2025
The company, formerly part of Johnson & Johnson, says it is taking steps ‘to accelerate profitable growth.'
